A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Bank Of Cyprus Oncology Centre, Stróvolos

German Oncology Center, Limassol

Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON, Barcelona

Klinicki bolnicki centar Zagreb, Zagreb

National Taiwan University Hospital, Taipei

National Cancer Center, Goyang-si

Oncomed-System, Belgrade

University Hospital Medical Center Bezanijska kosa, Belgrade

TAIPEI VETERANS GENERAL HOSPITAL, Urology, Taipei

Seoul National University Bundang Hospital, Seongnam-si

C.H. Regional Reina Sofia - PPDS, Córdoba

Oncology Institute of Vojvodina, Kamenitz

START MADRID_Hospital Universiario Fundacion Jimenez Diaz, Madrid

START Madrid_Hospital Universitario HM Sanchinarro_CIOCC, Madrid

Hospital Regional Universitario de Malaga ? Hospital General, Málaga

Memorial Sisli Private Hospital, Istanbul

China Medical University Hospital, Taichung

Hospital Universitario Virgen del Rocio, Seville

Inonu University Faculty of Medicine Turgut Ozal Medical Center, Malatya

Hospital Clinico Universitario de Valencia, Valencia

General Hospital Pula, Pula

Namik Kemal University, Alt?nova

National Cheng Kung University Hospital, Tainan City

Medical Oncology Associates, Spokane

Tianjin Cancer Hospital, Tianjin

Chongqing Sanxia Central Hospital, Chongqing

IASO Obstetrics Gynecology Clinic, Marousi

University General Hospital of Patras, Pátrai

Interbalkan Medical Center of Thessaloniki, Thessaloniki

St. Luke's Hospital, Thessaloniki

Seoul National University Hospital, Seoul

Asan Medical Center - PPDS, Seoul

ICO l?Hospitalet ? Hospital Duran i Reynals, L'Hospitalet de Llobregat

Hospital del Mar, Barcelona

Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara

Gazi University Medical Faculty, Ankara

Memorial Ankara Hastanesi, Ankara

Medical Park Seyhan Hospital, Seyhan